Back

Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart

31 August 2026 (12:50 - 13:00)
Organised by: Logo
Congress Presentation Part of: Transforming heart failure with next-generation therapies and mechanisms Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ying Wang

(China)

4 More presentations in this session

Presentation thumbnail
Phase Ib study of intravenous HRS-9057, an arginine vasopressin V2 receptor antagonist, versus oral tolvaptan in congestive heart failure with volume overload despite prior diuretic therapy
Professor W. Ou (CN)
Abstract
Presentation thumbnail
Comparative effectiveness of finerenone versus spironolactone in patients hospitalized with heart failure: a prospective cohort study
Doctor R. Xiao (Chongqing, CN)
Abstract
Presentation thumbnail
Optimizing mineralocorticoid receptor antagonist therapy with sodium zirconium cyclosilicate in heart failure
Doctor C. Basic (Gothenburg, SE)
Abstract
Presentation thumbnail
The effect of quality of life on all cause mortality in tafamidis treated vs. placebo ATTR-CM patients: post hoc analyses from the ATTR-ACT study
Doctor F. Cappelli (Florence, IT)
Abstract

Access the full session

Session thumbnail
Transforming heart failure with next-generation therapies and mechanisms

The Event

Event poster

ESC Congress 2026

31 August 2026 12:50 CET
You may be interested in
thumbnail
Congress Presentation
Heart failure and energy metabolism: the role of fatty acid transport proteins and cardiac lipotoxicity
29 June 2021
thumbnail
Congress Presentation
The gut microbiota metabolite phenylacetic acid regulates cardiac senescence through phenylacetylation modification of histones
30 August 2025
thumbnail
Congress Presentation
Human hyperpolarized 1-13C pyruvate CMR and adenosine stress test
29 August 2021
thumbnail
Congress Presentation
Phenotypic screening identifies HDAC6 inhibitors as cardioprotective agents in BAG3 cardiac-knockout mouse model of dilated cardiomyopathy
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources